The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an
about
Corticosteroids for the treatment of Duchenne muscular dystrophyCurrent and emerging treatment strategies for Duchenne muscular dystrophyAssessment and management of respiratory function in patients with Duchenne muscular dystrophy: current and emerging optionsNutraceuticals and Their Potential to Treat Duchenne Muscular Dystrophy: Separating the Credible from the ConjectureAnimal models of Duchenne muscular dystrophy: from basic mechanisms to gene therapyLong term natural history data in ambulant boys with Duchenne muscular dystrophy: 36-month changes.Cooperative International Neuromuscular Research Group Duchenne Natural History Study demonstrates insufficient diagnosis and treatment of cardiomyopathy in Duchenne muscular dystrophyAssessment of intramuscular lipid and metabolites of the lower leg using magnetic resonance spectroscopy in boys with Duchenne muscular dystrophy.The 6-Minute Walk Test and Person-Reported Outcomes in Boys with Duchenne Muscular Dystrophy and Typically Developing Controls: Longitudinal Comparisons and Clinically-Meaningful Changes Over One Year.Upper limb strength and function changes during a one-year follow-up in non-ambulant patients with Duchenne Muscular Dystrophy: an observational multicenter trial.Genetic modifiers of ambulation in the Cooperative International Neuromuscular Research Group Duchenne Natural History StudyLarge-scale serum protein biomarker discovery in Duchenne muscular dystrophyImproving clinical trial design for Duchenne muscular dystrophy.Discovery of Metabolic Biomarkers for Duchenne Muscular Dystrophy within a Natural History Study.Can Quantitative Muscle Strength and Functional Motor Ability Differentiate the Influence of Age and Corticosteroids in Ambulatory Boys with Duchenne Muscular Dystrophy?Prednisone/prednisolone and deflazacort regimens in the CINRG Duchenne Natural History Study.Duchenne Regulatory Science Consortium Meeting on Disease Progression Modeling for Duchenne Muscular DystrophyAbsence of Dystrophin Disrupts Skeletal Muscle Signaling: Roles of Ca2+, Reactive Oxygen Species, and Nitric Oxide in the Development of Muscular Dystrophy.The NorthStar Ambulatory Assessment in Duchenne muscular dystrophy: considerations for the design of clinical trials.Practice guideline update summary: Corticosteroid treatment of Duchenne muscular dystrophy: Report of the Guideline Development Subcommittee of the American Academy of NeurologyReachable workspace and performance of upper limb (PUL) in duchenne muscular dystrophy.Multicenter prospective longitudinal study of magnetic resonance biomarkers in a large duchenne muscular dystrophy cohort.DMD genotypes and loss of ambulation in the CINRG Duchenne Natural History Study.Association Study of Exon Variants in the NF-κB and TGFβ Pathways Identifies CD40 as a Modifier of Duchenne Muscular Dystrophy.Corticosteroid Treatment and Growth Patterns in Ambulatory Males with Duchenne Muscular Dystrophy.Non-Ambulant Duchenne Patients Theoretically Treatable by Exon 53 Skipping have Severe Phenotype.Identification of serum protein biomarkers for utrophin based DMD therapy.Drug Discovery of Therapies for Duchenne Muscular Dystrophy.Short stature and pubertal delay in Duchenne muscular dystrophy.Longitudinal community walking activity in Duchenne muscular dystrophy.Integrated care of muscular dystrophies in Italy. Part 1. Pharmacological treatment and rehabilitative interventionsAssociations between timing of corticosteroid treatment initiation and clinical outcomes in Duchenne muscular dystrophy.Outside in: The matrix as a modifier of muscular dystrophy.Sleep Disordered Breathing in Duchenne Muscular Dystrophy.Variables associated with upper extremity function in patients with Duchenne muscular dystrophy.Rehabilitative technology use among individuals with Duchenne/Becker muscular dystrophy.Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy.Health services received by individuals with duchenne/becker muscular dystrophy.Functional changes in Becker muscular dystrophy: implications for clinical trials in dystrophinopathiesPatients with Duchenne and Becker muscular dystrophies are not more asymmetrical than healthy controls on timed performance of upper limb tasks.
P2860
Q24185788-4A1BDCB9-8CC9-4B15-898C-7BDACBDA31B7Q26741535-F39206B4-CDDC-4643-9A84-74AA870D4ABCQ26785627-81CA1DAB-78BF-4306-86E1-B63710764AE0Q28072269-DA9DE3A6-A115-4662-9326-390E0D80E4FEQ28084979-163C7C41-B7DB-4DDA-A945-991B20DED8ACQ30856806-7EB5C948-8C65-47FB-B033-76388B6F588DQ33844719-94A07125-838E-4553-968E-EF0F7601E197Q34081572-1E2FD8DC-FB2D-4A23-A462-36963BF14B22Q34836557-DC37EFD2-D55D-4D3D-95D5-0A9E8906942FQ35038830-91512A8D-027E-4DE9-8FAC-3CFAD521E62EQ35495274-A17E1529-A694-4D62-BDB9-855D2466FB65Q35740280-16ED96B1-C9F3-41FD-A8DF-789DE9C6A53AQ35755174-8A287C27-9D99-4C03-B21C-97DC7DA566FDQ35991086-3489AF97-C9E5-4BA9-9712-7838F43667F3Q36097194-03C9D499-030C-4253-BBBE-FC98C85AD104Q36155677-9194A17E-4B17-449C-A251-2DE3A2A63A68Q36287980-B76880EE-0C18-4DD0-9B40-258F96AF6D37Q36422465-3A48F18A-8FDC-4A4D-9C87-36EEE132707EQ36577433-52250888-F4FA-4C89-A443-E5A5A9ABDDF5Q36638831-8BCE08FE-F20E-4087-821F-ACA4396D00E2Q36654988-3258CC9E-8950-4F8B-A374-DCE37151AD32Q37114363-D634511C-0278-426A-84D0-9AF71BA528B9Q37158951-532ED930-9511-441B-A436-FCEC31592338Q37396900-91CABC1D-BF2D-4725-9762-B14E36038163Q37400938-F4F5B479-ADE0-4DC7-8C5F-408D709308B8Q37589614-D78274C1-032A-4071-89B9-71F27F74483AQ37676311-7DA96243-2971-4AF8-BE77-5E8FA539A721Q38480698-D09E1775-3741-4F11-88B0-40232E32A486Q38542566-3438E0F4-9D51-4C5E-B35C-F5B4CD8989B5Q38686541-5B30A100-982B-4483-A153-8B4A3DD15C06Q38687534-C24EC1D0-E305-472E-97AC-21BAB80B790BQ38711641-A127E95A-EAF7-4479-9A4A-6004190BE20AQ39052032-815AB8EC-5D4A-49EF-85F0-3B1962E92396Q39233391-B90E3B8B-61C5-4066-8CD4-E7B62E001675Q39675281-E52DCB5E-CAA1-45FD-B826-F26BD2DD4001Q39929510-4BE3D38C-12BD-4887-90CB-6FC67413346AQ40316979-BAB0C18A-E298-4E4D-A855-931A23CA3A7FQ40868304-DF283489-DED2-43AC-97DB-6AA6617AC25DQ40991213-2C3C358E-E1B9-4AB3-BD57-0EB201536694Q41111026-CACF0C32-48C3-4E97-8C19-2A50DD283ED0
P2860
The cooperative international neuromuscular research group Duchenne natural history study: glucocorticoid treatment preserves clinically meaningful functional milestones and reduces rate of disease progression as measured by manual muscle testing an
description
2013 nî lūn-bûn
@nan
2013 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
The cooperative international ...... ed by manual muscle testing an
@ast
The cooperative international ...... ed by manual muscle testing an
@en
type
label
The cooperative international ...... ed by manual muscle testing an
@ast
The cooperative international ...... ed by manual muscle testing an
@en
prefLabel
The cooperative international ...... ed by manual muscle testing an
@ast
The cooperative international ...... ed by manual muscle testing an
@en
P2093
P2860
P356
P1433
P1476
The cooperative international ...... ed by manual muscle testing an
@en
P2093
Adrienne Arrieta
Avital Cnaan
CINRG Investigators
Diana M Escolar
Eric P Hoffman
Erik K Henricson
Fengming Hu
Julaine M Florence
Paula R Clemens
P2860
P356
10.1002/MUS.23808
P577
2013-05-06T00:00:00Z